Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Burlington Stores Inc (BURL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Burlington Stores Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Burlington Stores Inc trades at $327.72 (market cap $20.63B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Burlington Stores Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BURL | |
|---|---|---|
Market Cap | $39.89B | $20.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $347.82 |
52-Week Low | $278.09 | $242.43 |
Enterprise Value | $38.15B | $25.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Burlington Stores (BURL) trades at $327.72, up 1.95% today, with strong technical momentum and consistent earnings beats. The stock shows bullish moving averages and is near its 52-week high. Recent quarters have exceeded EPS expectations, with Q1 2026 actual EPS of $2.01 beating the $1.80 estimate. Financials reveal robust revenue growth, with 2025 revenue at $10.63B and net income of $503.64M, while analyst sentiment remains overwhelmingly positive with 94% buy ratings.
BURL's outlook is favorable, driven by margin expansion and store productivity gains, but risks include high valuation multiples and competitive retail pressures. The consensus price target of $364.40 suggests upside potential, though investors should monitor debt levels and consumer spending trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
